Instituto Rosenbusch (BUE:ROSE) Other Stockholders Equity: ARS8,051 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
37 GF Score
Price ARS158.50
GF Value ARS62.23
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Other Stockholders Equity?

Instituto Rosenbusch BUE:ROSE +0.96% 37 Other Stockholders Equity is ARS8,051 Mil as of Dec. 2025. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS62.23 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Instituto Rosenbusch's Other Stockholders Equity for the quarter that ended in Dec. 2025 was ARS8,051 Mil.

Instituto Rosenbusch's quarterly Other Stockholders Equity increased from Jun. 2025 (ARS7,072 Mil) to Sep. 2025 (ARS7,557 Mil) and increased from Sep. 2025 (ARS7,557 Mil) to Dec. 2025 (ARS8,051 Mil).

Instituto Rosenbusch's annual Other Stockholders Equity increased from Dec. 2023 (ARS5,975 Mil) to Dec. 2024 (ARS7,992 Mil) and increased from Dec. 2024 (ARS7,992 Mil) to Dec. 2025 (ARS8,051 Mil).

Instituto Rosenbusch Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Other Stockholders Equity Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 747.43 2,498.80 5,974.50 7,992.15 8,050.54

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,992.15 6,600.32 7,072.50 7,556.79 8,050.54
BUE:ROSE
37GF Score
Instituto Rosenbusch SA BUE:ROSE
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ARS8,051 Mil mean?
Instituto Rosenbusch (BUE:ROSE) has a Other Stockholders Equity of ARS8,051 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Other Stockholders Equity too high?
Instituto Rosenbusch's current Other Stockholders Equity is ARS8,051 Mil. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Other Stockholders Equity compare to ZTS and UTHR?
Instituto Rosenbusch's Other Stockholders Equity of ARS8,051 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Other Stockholders Equity is ARS8,051 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS62.23, compared to a current price of ARS158.50 — trading 154.7% above its estimated fair value. The current Other Stockholders Equity is ARS8,051 Mil. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Other Stockholders Equity is ARS8,051 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS158.50 is trading 154.7% above its estimated GF Value™ of ARS62.23. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Other Stockholders Equity: ARS8,051 Mil
  • GF Value™: ARS62.23 vs. price of ARS158.50 (154.7% above fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score

Get the complete analysis for BUE:ROSE

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS158.50
Price
ARS62.23
GF Value